ReviewHerzschrittmachertherapie & Elektrophysiologie2026
Imaging phenotypes and substrates in ventricular tachycardia.
Review in Herzschrittmachertherapie & Elektrophysiologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventricular tachycardia (VT) remains challenging, as the underlying substrate is heterogeneous and not adequately described by scar burden alone. Imaging is increasingly used to identify structural heart disease, characterize myocardial abnormality, and support VT ablation planning. Distinct imaging findings reflect specific myocardial phenotypes and substrate architectures, such as ischemic scar, nonischemic fibrosis, inflammatory injury, and fibrofatty remodelling. These phenotypes do not represent the same arrhythmic substrate and do not carry the same implications for mechanism, procedural strategy, or follow-up. This review discusses VT in terms of imaging phenotype and substrate rather than scar alone. It also summarizes how imaging can define substrate location, depth, tissue composition, and spatial distribution, and how this may improve understanding of the arrhythmic ventricle. The therapeutic implications of this framework are then discussed, including relevance for treatment planning, interpretation of treatment effect, and assessment of recurrence. Finally, current limitations and future directions of imaging-based substrate assessment in VT are addressed.
Indexed as
Identifiers
42489881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.